



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكرو فيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



# **Correlation of Serum Uric Acid Levels with Coronary Flow in Patients with ST-segment Elevation Myocardial Infarction undergoing Primary Coronary Intervention**

Thesis

*Submitted for Partial Fulfillment of  
Master's Degree in Cardiology*

By

***Abdelrahman Ahmed Abdelrahman Sharafeldin***

*M.B.B.Ch. Faculty of Medicine, Misr University for Science and Technology*

Under Supervision of

**Prof. Dr. Walid Abdel Azim El Hammady**

*Professor of Cardiology*

*Faculty of Medicine, Ain Shams University*

**Dr. Walid Mohamed Sallam**

*Lecturer of Cardiology*

*Faculty of Medicine, Ain Shams University*

Faculty of Medicine  
Ain Shams University  
Cairo - Egypt - 2021



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَدَانِكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Walid Abdel Azim El Hammady**, Professor of Cardiology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr. Walid Mohamed Sallam**, Lecturer of Cardiology, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Abdelrahman Ahmed Abdelrahman Sharafeldin**

# List of Contents

Title	Page No.
List of Tables.....	i
List of Figures .....	iii
List of Abbreviations.....	v
Introduction .....	1
Aim of the Work .....	3
Review of Literature	
▪ Hyperuricemia .....	4
▪ No Reflow Phenomenon .....	19
Patients and Methods.....	42
Results.....	50
Discussion .....	68
Limitations.....	72
Summary .....	73
Conclusion .....	75
Recommendations .....	76
References .....	77
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table 1:</b>	Risk factors and proposed etiologies of coronary no-reflow phenomena .....	25
<b>Table 2:</b>	The demographic data and risk factors among the studied group. ....	50
<b>Table 3:</b>	Comparison between hyperuricemia and normal group as regard demographic data, risk factors and type of MI. ....	52
<b>Table 4:</b>	Comparison between both groups regarding angiographic TIMI flow score & Myocardial Blush Grade and thrombus grade.....	54
<b>Table 5:</b>	Comparison of angiographic findings of both groups between hyperuricemia and normal group regarding No of vessels, CV, echocardiographic finding and UA.....	58
<b>Table 6:</b>	Comparison of echocardiographic findings of both groups between hyperuricemia and normal group regarding No of vessels, CV, echocardiographic finding and UA.....	59
<b>Table 7:</b>	Comparison between hyperuricemia and normal group regarding laboratory investigations.....	61
<b>Table 8:</b>	Comparison between hyperuricemia and normal group regarding MACE.....	63
<b>Table 9:</b>	Comparison between patients with TIMI III and those without regarding demographic data, hyperuricemia, risk factors, MBG III, thrombus garde and EF.....	64
<b>Table 10:</b>	Logistic regression analysis for factors associated with TIMI III.....	65



# List of Tables *cont...*

Table No.	Title	Page No.
<b>Table 11:</b>	Comparison between patients with BMG III and those without regarding demographic data, hyperuricemia, risk factors, TIMI III, thrombus grade and EF.....	66
<b>Table 12:</b>	Logistic regression analysis for factors associated with MBG III.....	67

# List of Figures

Fig. No.	Title	Page No.
<b>Figure 1:</b>	<b>A,</b> No reflow is a process that starts during the ischemic period and then increases during reperfusion. <b>B,</b> Various mechanisms are implicated in the genesis of the no-reflow phenomenon. ....	21
<b>Figure 2:</b>	The gender distribution among the studied group. ....	51
<b>Figure 3:</b>	The incidence of risk factors among the studied group. ....	51
<b>Figure 4:</b>	Comparison between hyperuricemia and normal group as regard age. ....	53
<b>Figure 5:</b>	Comparison between hyperuricemia and normal group as regard the incidence of risk factors. ....	53
<b>Figure 6:</b>	Comparison between hyperuricemia and normal group regarding TIMI flow score before and after PCI. ....	55
<b>Figure 7:</b>	Comparison between hyperuricemia and normal group regarding TIMI III. ....	55
<b>Figure 8:</b>	Comparison between hyperuricemia and normal group regarding MBG after PCI. ....	56
<b>Figure 9:</b>	Comparison between hyperuricemia and normal group regarding MBG III. ....	56
<b>Figure 10:</b>	Comparison between hyperuricemia and normal group regarding thrombus grade. ....	57

## List of Figures *cont...*

Fig. No.	Title	Page No.
<b>Figure 11:</b>	Comparison between hyperuricemia and normal group regarding EF.....	60
<b>Figure 12:</b>	Comparison between hyperuricemia and normal group regarding UA. ....	60
<b>Figure 13:</b>	Comparison between hyperuricemia and normal group regarding HB. ....	62

# List of Abbreviations

Abb.	Full term
<i>CAD</i>	<i>Coronary artery disease</i>
<i>CBC</i>	<i>Complete blood picture</i>
<i>DM</i>	<i>Diabetes Mellitus</i>
<i>ECG</i>	<i>Electrocardiogram</i>
<i>ESRD</i>	<i>End stage renal disease</i>
<i>FH</i>	<i>Family history</i>
<i>HTN</i>	<i>Hypertension</i>
<i>IC</i>	<i>Intracoronary</i>
<i>INR</i>	<i>International normalized ratio</i>
<i>IS</i>	<i>Infarct size</i>
<i>IV</i>	<i>Intravenous</i>
<i>MBG</i>	<i>Myocardial blush grade</i>
<i>MI</i>	<i>Myocardial infarction</i>
<i>MVO</i>	<i>Micro vascular occlusion</i>
<i>PCI</i>	<i>Percutaneous coronary intervention</i>
<i>PPCI</i>	<i>Primary percutaneous coronary intervention</i>
<i>PTD</i>	<i>Pain to door</i>
<i>SD</i>	<i>Standard deviation</i>
<i>SPSS</i>	<i>Statistical Package for the Social Science</i>
<i>STEMI</i>	<i>ST-segment elevation myocardial infarction</i>
<i>TIMI</i>	<i>Thrombolysis in myocardial infarction risk score</i>

# INTRODUCTION

Acute myocardial infarction is the most severe manifestation of coronary artery disease, which causes more than 2.4 million deaths in the USA, more than 4 million deaths in Europe and northern Asia, and more than a third of deaths in developed nations annually (*Yeh et al., 2010*). Primary PCI is the treatment of choice for acute coronary syndrome with STEMI (*Nichols et al., 2014*). The reopening of the culprit coronary artery, however, does not necessarily translate into improved tissue perfusion, despite imaging evidence that the target stenosis was adequately removed or bypassed. This phenomenon is known as **No-Reflow**.

Hyperuricemia is one of the important risk factors for CAD. It is associated with an increased risk of mortality and morbidity.

While many studies have proved the correlation between hyperuricemia and major cardiac events in patients presenting with STEMI and undergoing primary PCI the assessment of the relation between hyperuricemia and coronary flow in patients presenting with STEMI and undergoing primary PCI has not been fully evaluated (*Ozgur et al., 2017*).

Hyperuricemia is known to be associated with cardiovascular disease (CVD), such as coronary artery disease (CAD), stroke and hypertension (*Kim et al., 2010*) but the role

of serum uric acid (SUA) as an independent risk factor for CVD remains unclear. Many epidemiologic studies have shown that hyperuricemia is frequently noted in patients either with CVD or at a high risk of CVD, such as hypertension, CAD, stroke, heart failure, metabolic syndrome, and peripheral vascular disease [1]. Most investigators reasoned that SUA may become passively elevated due to the effects of insulin resistance, renal vasoconstriction, and reduced estimated glomerular filtration rate (eGFR) to reduce uric acid excretion by the kidneys (*Zhao et al., 2017*). However, experimental studies have suggested that SUA may have an independent modulatory or causal role in these conditions (*Mazzali et al., 2010*). Consistent with these findings, an elevated SUA has been consistently found to predict the development of CAD (*Kim et al., 2010*). Unfortunately, because many of the subjects with hyperuricemia have comorbidities, it can be difficult to differentiate the role of SUA from the coexistence of the other comorbid conditions. Although multivariable analysis can be used to control for these other conditions, multivariable analysis can be misleading if the associated risk factors are causally linked (*Kuwabara et al., 2017*). The limitations associated with multivariable analysis as a means for determining causation are well known (*Zhao et al., 2017*).



## **AIM OF THE WORK**

The aim of this work is to study the effect of Uric acid level as a preventive tool for No-reflow phenomenon in patients presented with acute STEMI undergoing primary PCI.